KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
Shyam SrinivasanChetan Anil DhamneNikhil PatkarGaurav ChatterjeeNirmalya Roy MoulikAkanksha ChichraAneeta PallathPrashant Ramesh TembhareDhanalaxmi ShettyP G SubramanianGaurav NarulaShripad BanavaliPublished in: Pediatric blood & cancer (2023)
Exon 17 KIT mutations serve as an important predictor of relapse in RUNX1::RUNX1T1 pediatric AML. In addition, a high KIT VAF may predict poor outcomes in these patients. These results emphasize the need to incorporate KIT mutational analysis into risk stratification for pediatric CBF-AML.
Keyphrases
- acute myeloid leukemia
- transcription factor
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- type diabetes
- metabolic syndrome
- adipose tissue
- patient reported outcomes
- young adults
- acute lymphoblastic leukemia
- skeletal muscle
- childhood cancer
- weight loss
- free survival